
Last updated: 2026-09-16 11:41:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Vaxcyte, Inc. (PCVX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $59.20, with a market capitalisation of $8.86B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $30.81 to $65.00. This page covers its latest market performance, valuation, price trends and company information.
$8.86B | |
$59.70 | |
$121.06 | |
$15.51 | |
$59.54 | |
1.59M | |
1.30M | |
-- | |
$65.00 | |
$30.81 | |
-- | |
-- |
Vaxcyte, Inc. (PCVX) is trading at $59.75 in pre-market trading as of 2026-09-15 23:31:00, up 0.34% ($0.20) from the previous close of $59.54
Pre-market trading shows how investors are pricing PCVX before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Vaxcyte, Inc. (PCVX) moved from $61.16 to $59.20, representing a decline of 3.20% ($1.96).
The stock traded between $58.18 and $61.78 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 1.34 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 83.0%
PCVX is currently trading at $59.20, placing it 83.0% of the way from its 52-week low of $30.81 to its 52-week high of $65.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 507 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Vaxcyte, Inc. (PCVX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.